{"id":"W4412647773","doi":"10.1016/j.eururo.2025.05.019","title":"First-line Pembrolizumab Plus Lenvatinib for Advanced Non–clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial","year":2025,"lang":"en","type":"article","venue":"European Urology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval","funders":"","keywords":"Medicine; Lenvatinib; Pembrolizumab; Renal cell carcinoma; Internal medicine; Oncology; Immunotherapy; Cancer; Sorafenib; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002225755,0.00078958,0.002113885,0.0003279199,0.000259308,0.001456487,0.0005614455,0.0007298019,0.003607084],"category_scores_gemma":[0.001865999,0.0003016243,0.002224337,0.0005182566,0.0003613283,0.001532371,0.0003712068,0.003191869,0.0006964682],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001141457,"about_ca_system_score_gemma":0.0009525851,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001048654,"about_ca_topic_score_gemma":0.004882896,"domain_scores_codex":[0.9993829,0.0002513545,0.00003459021,0.00009535522,0.000113064,0.0001228152],"domain_scores_gemma":[0.9993992,0.0001832592,0.000150553,0.00005056185,0.00005943828,0.0001569513],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3685347,0.005106148,0.008423111,0.006978402,0.01400717,0.000258222,0.0002483676,0.007270936,0.008894597,0.001475731,0.05393649,0.5248662],"study_design_scores_gemma":[0.7576733,0.07311065,0.05308223,0.001433089,0.01502815,0.001343733,0.0002314662,0.004135991,0.003182611,0.004366418,0.08626264,0.0001497825],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8044989,0.1413187,0.003138183,0.00703941,0.002609176,0.001746812,0.01324642,0.0004440388,0.02595846],"genre_scores_gemma":[0.9291417,0.03418075,0.003237771,0.007356735,0.000941337,0.001078625,0.01573678,0.0001172506,0.008209062],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003607084,"threshold_uncertainty_score":0.01206696,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02573848624349531,"score_gpt":0.2798555129792575,"score_spread":0.2541170267357622,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}